3D Medicines Inc is a holding company mainly engaged in the research and development (R&D) and commercialization of biopharmaceuticals. The Company focuses on the discovery, development and commercialization of innovative drugs in the field of cancer chronic disease treatment, and also lays out the field of cancer pain management. The Company has built a complete set of internal R&D systems, and has covered the entire process from drug discovery, preclinical development, clinical trials, and registration. The Company's first marketed drug, Envafolimab, is a subcutaneously injected PD-L1 inhibitor for the treatment of pan-tumor types. The Company also has a number of innovative drug research and development pipelines. The Company primarily operates in the domestic Chinese market. *
Please click to see notes of Issued Shares.Issued Shares (excluding treasury shares)
258,177,000 (as at 30 Jun 2025)
Industry
Healthcare - Pharmaceuticals & Biotechnology - Biotechnology Industry Classification (HSIC) is provided by Hang Seng Indexes Company Limited. Please see the . (HSIC)
Industry Classification (CSIC) is provided by China Securities Indexes Co., Ltd. and only available for companies dually listed in Hong Kong and Shanghai. Please see the . (CSIC)
Listing Date
15 Dec 2022
Financial Year Ends
31 Dec 2024
Chairman
Gong Zhaolong
Principal Office
19th Floor
Golden Centre
188 Des Voeux Road Central
Hong Kong
Place of Incorporation
Cayman Islands
Listing Category
Primary Listing
Primary Market
Depositary
DR Ratio
Description
Amount Outstanding
-
-
Subscription Rights per Unit
Subscription price/Strike price
Listing Date
The entitlement ratio in general represents the number of warrants required to be exercised into one share or one unit of the underlying asset (subject to any adjustments as may be necessary to reflect any capitalization, rights issue, distribution or the like).Entitlement Ratio
Subscription Period
Underlying Stock Code
Trading Currency